Immune checkpoint inhibitors targeting programmed death-1 and its ligand (PD-[L]1) revolutionized the therapeutic landscape in cancer over the last decade, offering improved health outcomes across a wide range of hematological and solid malignancies (13–15). This evidence concerns the gene CD274 and cancer.